Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 01, 2025 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target

PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
June 25, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Global mRNA Synthesis and Manufacturing Market to Increase at a Steady Growth Rate of ~4% by 2032 | DelveInsight

New York, USA, June 25, 2025 (GLOBE NEWSWIRE) -- Global mRNA Synthesis and Manufacturing Market to Increase at a Steady Growth Rate of ~4% by 2032 | DelveInsightThe growing incidence of infectious...
June 25, 2025 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)

- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25,...
June 05, 2025 10:07 ET | Source: Exactitude Consultancy

Nanoparticles Market is expected to reach USD 120 billion by 2034, driven by a 7.2% CAGR and expanding applications | Exactitude Consultancy

Luton, Bedfordshire, United Kingdom, June 05, 2025 (GLOBE NEWSWIRE) -- The global nanoparticles market is witnessing remarkable growth, with its valuation estimated to reach approximately USD 60...
June 03, 2025 07:30 ET | Source: Cognition Therapeutics, Inc.

Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Dr. James Galvin of the University of Miami to Serve as Lead Investigator First Site Initiated: Banner Sun Health Research Institute PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition...
May 28, 2025 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today...
May 13, 2025 08:30 ET | Source: AstuteAnalytica India Pvt. Ltd.

Oilfield Communication Market is Poised to Reach Valuation of US$ 6.16 billion By 2033 | Astute Analytica

Chicago, May 13, 2025 (GLOBE NEWSWIRE) -- The global oilfield communication market was valued at US$ 3.82 billion in 2024 and is expected to reach US$ 6.16 billion by 2033, growing at a CAGR of...
May 09, 2025 10:00 ET | Source: SNS Insider pvt ltd

Sodium Chlorite Market to Reach USD 415.61 Million by 2032, Driven by Water Treatment and Sanitation Demand | Report by SNS Insider

Austin, May 09, 2025 (GLOBE NEWSWIRE) -- The Sodium Chlorite Market Size was valued at USD 258.76 Million in 2023 and is expected to reach USD 415.61 Million by 2032, growing at a CAGR of 5.41% over...
May 09, 2025 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical...
May 08, 2025 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy

Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to placebo Observed GA lesion area was reduced by 28.2% at 18 months compared to placebo Dry AMD results validate...